Summary.-The relationship between the utilization of 3H-thymidine in situ ([3H]-TdR fractional incorporation or TFI) and tumour growth delay after treatment with various cytotoxic agents has been examined. It is shown that (a) it is not possible to predict tumour growth delay, or to select the most effective agent, from changes in TFI 1 day after treatment; (b) there is a good correlation between tumour growth delay and the time for recovery of TFI to the pretreatment level; (c) there is a relationship within a tumour line between the depression of TFI 4 days after treatment and growth delay induced by the same treatment. This relationship appears to be independent of the mechanism by which the agent exerts its cytotoxic effect.
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THE accurate measurement of tumour response to a cytotoxic agent is necessary before we can evaluate the efficacy of individual agents, or combinations of agents. In the laboratory under defined conditions, measurements such as tumour growth delay, in vitro clonogeInic cell survival (Steel and Adams, 1975) , or the proportion of animals cured when treatment is initiated soon after tumour-cell inoculation, have been used to assess quantitatively the valtue of new and established agents. At present there is no single method of assessment that can be used with absolute confidence with every drug-tumour combination (Connors and Phillips, 1975) , but tumour growth inhibition probably serves as the most useful parameter to evaluate drug efficacy in the laboratory.
In the clinic, evaluation of agents becomes far more difficult, and partial or complete tumour regression has been taken to indicate the usefulness of an agent. However, the methods used to measure regression are subject to considerable error (Moertel, 1976) and com- parison of results from various clinical trials canI to lead to confuision over the clinical value of an agent (Carter and Friedman, 1974) . Tumour volume regression per se must be regarded with caution, as Steel and Adams (1975) have shown a very small volume regression in a rodent carcinoma after treatment with cyclophosphamide, when the surviving fraction of clonogenic cells was about 10-6. Clinically, the measurement of tumour growth inhibition may be more sensitive as an indicator of drug effect, but at present is practical for only a few tumour sites.
Many attempts have been made to relate changes in the in vitro incorporation of radiolabelled precursors into tumour DNA, to the subsequent patient response. In order to predict the tumour sensitivity in an individual patient, tumour biopsy material has been incubated with various cytotoxic agents, and the drug producing the greatest inhibition of DNA precursor utilization has generally been regarded as potentially the most active against that tumour (Wheeler, Dendy and Dawson, 1974; Wolberg, 1971) . Other workers have compared the differential response between the neoplastic biopsy and normal tissue, drug selection being determined by this differential (Tisman, Herbert and Edlis, 1973; Jzsak et al., 1971) . Alternatively, serial tumour biopsies have been taken after treatment and the radiolabelled precursor utilization in vitro compared with that in pretreatment material (Murphy et al., 1975 : Wheeler et al., 1974 : Sky-Peck, 1971 ).
In previous studies with two transplantable murine tumours (Houghton and Taylor, 1977a) Tumour lines.-The 4 human colonic tumour lines used in this study wiill be described in greater detail in a subsequent publication (Houghton and Taylor, in preparation) . Briefly they constitute the following, listed in decreasing order of differentiation:
HxHC1-a moderately wiell differentiated adenocarcinoma of the ascending colon, maintained only in female mice.
HxGC3-a poorly differentiated adenocarcinoma of the transverse colon, maintained in male mice. HxVRC5 a poorly differentiated adenocarcinoma of the caecum, maintained in male mice. Labelled thymidine fractional incorporation (TFI) assay.-The measurement of TFI has been described previously (Houghton and Taylor, 1977a) . Animals were given 25 [tCi 3H-6-TdR (Radiochemical Centre, Amersham, sp. act. 27 Ci/mmol) at various times after administration of the cytotoxic agent, and were killed 1 h later. Tumours were rapidly excised and frozen (-26°C) until being submitted to a modified Schmidt-Thannhauser extraction (Munro and Fleck, 1968) . In these experiments, tumours were weighed and homogenized in KOH (0-3M) and incubated in sealed tubes for 12 h at 37°C. Samples were cooled (2°C), neutralized with cold HCI (1M) and acidified to 0-2M With perchloric acid (PCA). After centrifugation, the supernatant was decanted, and the pellet was resuspended in cold PCA (0 2M). After further centrifugation, the supernatants of individual tumours were combined to give the non-incorporated fraction (i.e. acidsoluble and RNA) F1, for each individual tumour. DNA was extracted twice by incubating each resuspended pellet in PCA (1M) at 67°C. The combined DNA extracts constitute the incorporated radioactivity fraction (F 2) for each individual tumour. Fractional incorporation is calculated as: TFIJ F2 (ct/mmn) _< 100 F1+F2 (ct/min) Radioactivity was measured by liquid scintillation spectrometry (Intertechnique Ltd, Model SL40) as previously described (Taylor, Tew and Jones, 1976) .
In this study, the animals received a single i.p. injection of the cytotoxic agent. The highest dose of each agent used was lethal in 50% of animals (LD5) except in the case of tumour HxGC3 where the highest dose of cyclophosphamide studied was the LD1o.
RESULTS

TFI in untreated tumours
Initial studies showed that TFI decreased with increasing tumour mass in each of the 4 xenograft lines studied ( The relationship between early TFI changes and growth delay In each of the 4 tumour lines, the depression of TFI at 24 h after drug treatment has been compared with the subsequent growth delay with one of the following agents: cyclophosphamide (CY), 5-fluorouracil (FU), 1-(2-chloroethyl)-3-trans-4-methyl cyclohexyl)-l-nitrosourea (Me CCNU) or actinomycin D (Act D), at equi-toxic levels (LD5). The results are shown in Table I . Although a long
The relationship between TFI recovery time and growth delay Our previous study, using two transplantable rodent tumours, showed that the time taken for TFI to recover to the pretreatment level was similar to the duration of tumour growth inhibition for treatment with either CY or 6OCo radiation (Houghton and Taylor, 1977a Fig. 4 show that after treatment, even at doses inducing considerable growth inhibition, no volume regressions were found. In most cases, tumour growth continued at a reduced rate, but appeared to recover to that of untreated tumours (of the same line and weight) by the time they had grown to 4 times the treatment volume (marked by a horizontal arrow in Fig. 4 ). Taylor, 1977b, 1977c (Table Ill) . Consequently, an agent in- o00  50  70  150  80  ND  200  110  170  300  190  250  5 FU  50  0  0  100  0  0  150  35  0  200  60  30   12 MeCCNU 35  550  560  6 CY  50  20  0  100  60  70  150  340  290  200  600  580  6 FU  50  0  0  100  0  0 In the 4 tumour lines studied in this work, there is a clear relationship between growth delay and TFI recovery time (n 36, r-0 96). In one tumour line (HxELC2) we have been able to establish a relationship between TFI depression 4 days after treatment and growth delay (r-0 96) or TFI recovery time (r-086). The time at which such a relationship is established will probably vary with each tumour line, but "calibration" of a tumour line in this manner may allow rapid evaluation of single agents, or combinations of agents.
It is not certain whether any of the tumour-inhibitory effects presented in this study would be regarded as positive tumour responses in the clinic, for in each case the tumours have continued to grow after treatment, and the criterion of a 5000 reduction in the product of the tumour diameters has not been satisfied. However, that tumour growth inhibition has been induced ( Fig. 4a-d) is apparent when the growth curves for treated tumours are compared with those for untreated tumours.
Our data show that the TFI recovery time correlates with growth delay produced by the same treatment, and in the laboratory, where tumouir lines may be "calibrated", the assay may allow rapid assessment of the value of drug combinations and schedules. However, the data show that changes in utilization of [3H]TdR by tumours soon after the administration of cytotoxic agents are a poor indicator of tumour response in situ, and such results obtained 1 day after treatment must be regarded with caution.
